Gene Editing industry news
Never miss what your Gene Editing competitors ship.
15 updates from 7 Gene Editing companies this past week. We read them all so you don't have to.
✓ Start tracking competitors within minutes
✓ Receive updates on their activities
✓ No credit card required
150,000+ companies tracked · 137M URLs counted · Tracking since 2025 · GDPR compliant · EU infrastructure
This page collects Gene Editing industry news from the companies themselves. Parano.ai tracks 12 companies in this market, including Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, eGenesis, Intellia Therapeutics and 7 more, and turns what they publish and change into digestible intel reports, battlecards and sales enablement assets.
- Updates in the latest digest
- 15from 7 companies
- Latest digest covers
- Oct 15 to Oct 22, 2026
Most active in the last 7 days, mostly event pages and news posts:
eGenesis2 updates
Scribe Therapeutics2 updates
CRISPR Therapeutics1 update
Every summary links to its public source.
Gene Editing news this week
Oct 15 – Oct 22, 2026
This is last week's digest for Gene Editing. Get one built for your actual competitors →
Executive Summary
- CRISPR Therapeutics has appointed A.J. Silver as Chief Financial Officer, succeeding Raju Prasad, Ph.D.[1]
Precision BioSciences will deliver a late-breaking oral presentation on PBGENE-HBV clinical data at AASLD 2026, focusing on durable pgRNA loss in chronic hepatitis B patients.[2]
Sangamo Therapeutics announced a new auction process timeline for its clinical-stage chronic neuropathic pain program, ST-503.[3]
Metagenomi presented insights on its in vivo genome editing platform and lead program, MGX-001, at the ARM 2026 Cell & Gene Meeting on the Mesa.[4]
Intelliatx has moved into a new office and lab space designed to foster team collaboration.[5]
Beamtx and Scribe Therapeutics have amplified industry discussions regarding target/modality decisions and AI in drug discovery, respectively.[6][7]
7 sources
- Crisprtx — CRISPR Therapeutics Appoints A.J. Silver as Chief Financial Officer
- Precision BioSciences — Precision BioSciences to Present PBGENE-HBV Clinical Data at AASLD 2026
- Sangamo Therapeutics — Sangamo Therapeutics Shares Auction Timeline for ST-503 Program
- Metagenomi — Metagenomi Shares Insights on In Vivo Genome Editing Platform
- Intelliatx — Intelliatx Moves Into New Collaborative Office and Lab Space
- Beamtx — Beamtx Amplifies IRBM Post on Target and Modality Decisions
- Scribe Therapeutics — Ilmac Amplifies Brett Staahl's Keynote on AI in Drug Discovery
Tracking 7 Gene Editing vendors like this?
Tracking since 2025 · GDPR compliant · EU infrastructure
Latest Gene Editing company updates
Scribe Therapeutics to Present Epigenetic Silencing Data at ESGCT 2026
Intellia Sponsors HAEi Regional Conference in Ottawa
eGenesis Appoints Daniel Leblanc as Chief Manufacturing and Supply Officer
Tracking 7 Gene Editing vendors like this?
eGenesis Appoints Daniel Leblanc as Chief Manufacturing Officer
Editasmedicine to Present Research Posters at ESGCT
Scribe Therapeutics Shares Insights on AI-Driven CRISPR Engineering
CRISPR Therapeutics Appoints A.J. Silver as Chief Financial Officer
Gene Editing companies we track
- Beam Therapeutics
- CRISPR Therapeutics
- Editas Medicine
- eGenesis
- Intellia Therapeutics
- Mammoth Biosciences
- Metagenomi
- Precision BioSciences
- Prime Medicine
- Sangamo Therapeutics
- Scribe Therapeutics
- Verve Therapeutics
Parano.ai · Industry news · AI-Powered Competitive Intelligence